Micronized Antibodies in Polymeric Particles for Drug Delivery
Summary
USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.
What changed
The USPTO published a patent application (US20260090991A1) for compositions and methods of delivering large proteins via micronized antibodies encapsulated in polymeric particles. The application covers pharmaceutical formulations using specific polymer types, molecular weights, and antibody loadings to achieve minimal to no initial burst release. The compositions are designed for oral, subcutaneous, or percutaneous administration for antibody-based treatment regimens.
This is a published patent application, not a regulatory rule or guidance. No compliance actions are required from regulated entities. Companies developing antibody delivery systems may wish to review the claims to assess potential IP implications for their own R&D programs. The application was filed October 3, 2023, under Application No. 19115269.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS OF DELIVERING LARGE PROTEINS
Application US20260090991A1 Kind: A1 Apr 02, 2026
Inventors
Edith MATHIOWITZ, Aharon AZAGURY, Cameron BAPTISTA
Abstract
Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.
CPC Classifications
A61K 9/1647 A61K 9/0019 C07K 16/2839 C07K 2317/90
Filing Date
2023-10-03
Application No.
19115269
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.